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Abstract

•

• Lyme disease is caused by human infection with Borrelia
burgdorferi, a spirochete transmitted by the Ixodes tick
which is indigenous primarily to an increasingly large area
of the Northeast and Midwest United States.
• Manifestations of Lyme disease vary greatly, and can result
in significant neurologic symptoms associated with
complications of neuroborreliosis or neurologic Lyme
disease.
• Diagnosis and treatment of Lyme disease and its
complications has been a source of debate and confusion
for providers and patients alike.
• The purpose of this study was to investigate the
effectiveness and efficacy of antibiotic therapy in patients
with symptoms of neurologic Lyme disease.
• Through a review of literature related to the treatment
and outcomes of neurologic Lyme disease, it is determined
that current evidence based guidelines for
pharmacological treatment of neurologic Lyme disease are
appropriate when administered correctly. It is also
concluded that long term antibiotic therapy is not
appropriate for patients with symptoms of chronic Lyme
disease due to inadequate evidence to support improved
outcomes after antibiotic treatments.

•

•

•

Research Questions
•
• In patients with neurologic Lyme disease, does the
benefit of treating with antibiotics outweigh the
potential for adverse reactions and resistance to
antibiotics?
• Which antibiotics are most effective in treating
neurologic Lyme disease?

Introduction
•Although the disease process is relatively well understood,
suspicion of chronic or re-infection in Lyme disease persists.
•Diagnosis and treatment of Lyme disease and its
complications has been a source of debate and confusion for
providers and patients alike. The purpose of this study is to
investigate the effectiveness and efficacy of antibiotic
therapy in neurologic Lyme disease treatment to define best
practice guidelines in treating such patients.

Literature Review
•

•

•

Statement of the Problem
The best methods of diagnosis and treatment of neurologic
symptoms in Lyme disease remain poorly understood, and
therefore differing schools of thought exist regarding the
efficacy, timing, and benefit of antibiotic therapy in patients
with symptoms of neurologic Lyme disease.

•

Pathophysiology
It has been recognized that B. burdorferi causes chronic
infection as the bacteria has been isolated in skin, CSF,
synovial tissue, blood, synovial tissue, eye tissue and
myocardium. (Kaiser 1998)
A classic triad of conditions in neurologic Lyme
manifestations is said to exist including meningitis, cranial
neuropathy, and radicular neuropathy although the
conditions do not always occur together. (Wright, Riedel,
Talwani, & Gilliam, 2012)
There is little evidence to support the role of Borrelia
burgdorferi morphologic variants in the pathogenesis of
Lyme disease, and no evidence that they influence
treatment outcomes. (Lantos, Auwaerter, & Wormser,
2014)
Cognitive impairment without direct CNS infection may
result from Lyme encephalopathy, an immune modulated
disorder that clears after antimicrobial therapy and is
often confused with posttreatment or chronic Lyme
disease for which treatment is rarely indicated. (Halperin
2014)

•

•

Antibiotic Therapy
The recommendations for treatment of neurologic Lyme
disease are dependent on the duration of symptoms and
physical exam with IV ceftriaxone 2g or cefotaxime 2 g
daily for 10-28 days or penicillin G 18-24 mega U per day
for 10-28 days. (Wormser et al., 2006).
Recommended prophylactic treatment of Lyme disease
consists of a single 200 mg oral dose of doxycycline when
appropriate criteria have been met. (Wormser et al.,
2006)
Antibiotic therapy has not proven to be useful and is not
recommended for patients with chronic (>6 months)
subjective symptoms after recommended treatment
regimens for Lyme disease” (Lantos et al. 2010).
Klempner et al. (2001) concluded that there was no
significant symptomatic improvement over placebo after
30 days of treatment with ceftriaxone followed by 60
days of doxycycline 100 mg twice daily in patients with
symptoms of disseminated Lyme disease.
Sopi et al. (2011), concluded that antibiotics have
varying effects on different forms of Borrelia burgdorferi,
but there is little evidence of morphologic variants
persisting in vivo, thus altering antimicrobial treatments
to cover for such pathogens is not supported.
Conventional and commonly used monotherapy with
doxycycline and ceftriaxone demonstrated to be the most
effective against the most predominant spirochete form.
(Feng et al. 2015)
Kaplan et al. (2003), found no significant differences (z
scores of <-1) for any neuropsychological tests between
treatment and placebo groups.

Discussion
• Much of the controversy surrounding Lyme disease is
centered on the efficacy of treatment, specifically
antibiotic therapy for confirmed cases of disseminated
Lyme disease.
• It must be questioned whether the inherent risk of
adverse effects with lengthy courses of IV antibiotics
outweigh the possible benefit if the improvement in
symptoms is not statistically significant
• There is concern of adverse effects and increasing cost of
treatment with doxycycline as prophylaxis of disease
when clinical presentation suggests infection is unlikely.
• Disseminated symptoms are not effectively treated with
extended antibiotic treatment.
• No studies have confirmed the existence of morphologic
variants of B. burgdorferi contributing to disease
processes in human subjects.
• There is no evidence based argument to be made for
long term antibiotic treatment of chronic symptoms
attributed to infection with Borrelia burgdorferi .

Applicability to Clinical Practice
• Providing proper patient education on the topic may
contribute to avoidance of confusion and reduce anxiety
• Erythema migrans rash is helpful in suspicion of Lyme
disease, but other symptoms such as neuralgias, myalgias
and other disseminated symptoms are easily overlooked
or misdiagnosed.
• As healthcare providers it is our obligation to effectively
assess, diagnose and treat our patients in a manner that
will best serve the patient without the risk of
contributing any undue harm.
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